Abstract:
13-Aklyl-10-methylgon-4-en-3-ones possessing androgenic, anabolic, progestational activity are prepared from the correspondingly substituted 13-alkyl-10-methylgonan-4-ones wherein groups labile to mesylation are protected to permit selective mesylation of subsequently formed 4-hydroxy group, by converting the 4-one to its 3-hydroxy-methylene derivative, hydrolyzing the oximino group, mesylating the 4-hydroxy group, catalytically hydrogenating the unsaturation at the 4-position, and eliminating the 4-mexyloxy group to form the 4-en-3-one conjugated system.
Abstract:
A process for the conversion of A type prostaglandins to E type prostaglandins is disclosed. Heretofore unknown prostaglandin derivatives are utilized as intermediates in the process.
Abstract:
9-Oxo-15-substituted prostanoic acids, and intermediates for their preparation and for the preparation of other known prostaglandins are disclosed. The final products have bronchodilatory activity.
Abstract:
The topical application of 7-(5 Alpha -hydroxy-2 Beta -((3RS)-3hydroxy-3-methyl-trans-1-octenyl)-3 Alpha -methyl-1 Alpha cyclopentyl)-cis-6-heptenoic acid, 7-(5 Alpha -hydroxy-2 Beta ((3RS)-3-hydroxy-3-methyl-trans-1-octenyl)-1 Alpha -cyclopentyl)cis-5-heptenoic acid, or 7-(2 Beta -((3RS)-hydroxy-3-methyltrans-1-octenyl)-5-oxo-1 Alpha -cyclopentyl)-cis-5-heptenoic acid to a wound surface can be employed to attenuate bleeding. The compounds are prepared from the prostaglandin PGA2.